Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
Working with partners in private industry, government, and academia, MVI aspires to develop, by 2015, a malaria vaccine with protective efficacy equal to or greater than 30 percent against clinical disease and that lasts longer than one year. The program also aims to develop, by 2025, a vaccine with 80 percent or greater efficacy that lasts up to four years.
